Tag: Drug induced liver injury

While nonsteroidal anti-inflammatory drugs (NSAIDs) are a frequent cause of drug-induced liver injury (DILI) in some studies, accounting for roughly 10% of cases, the actual risk of clinically apparent hepatotoxicity from their use remains very low. This begs the question: what NSAID is least harmful to the liver for the general population?

While many liver cysts are benign and congenital, certain medications can induce or exacerbate their development. Research has identified a link between specific pharmacological agents, particularly anabolic steroids and certain hormonal therapies, and the formation of hepatic cysts and lesions. This article explores the medications that can cause liver cysts, the underlying mechanisms, and how to manage the associated risks for better liver health.

According to the NIH LiverTox database, tirzepatide (Mounjaro) is an exceedingly rare cause of clinically apparent acute liver injury. While uncommon, patients and clinicians still question if **can mounjaro cause liver damage** and what precautions are necessary. This guide explores the potential for liver-related side effects and the drug's overall impact on hepatic health.

While severe hepatic failure is a rare event, drug-induced liver injury is a known potential adverse effect of many disease-modifying therapies (DMTs) used for multiple sclerosis (MS). All patients should be informed about the potential for liver damage, as the incidence and underlying mechanisms can vary significantly between different MS drugs.

Liver test abnormalities have been reported in 10% to 50% of patients on long-term olanzapine therapy [1.2.2, 1.6.1]. The key question for many patients and clinicians is, **does olanzapine elevate liver enzymes** to a clinically significant degree, and what are the implications for treatment?

While highly rare, documented case reports indicate a possible link between doxycycline and gallbladder issues, including the development of gallstones (cholelithiasis) and cholestatic liver injury. The vast majority of patients take doxycycline without incident, but awareness of this potential adverse event is crucial for effective patient care.

Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and obesity [1.3.2, 1.9.5]. While effective, it's important to understand: what are the side effects of tirzepatide on the kidneys and liver?

According to a 2025 review, patients with underlying chronic liver diseases like Primary Biliary Cholangitis (PBC) have an increased risk for drug-induced liver injury, making it vital to know **what drugs should be avoided with PBC**. Navigating medications safely is crucial for managing the disease and preventing complications, including progression to cirrhosis.

Clopidogrel, the active ingredient in Plavix, is associated with serum enzyme elevations in 1% to 3% of patients during therapy, though clinically apparent liver injury is an exceptionally rare side effect. Consequently, the question "Does Plavix elevate liver enzymes?" can be answered with a qualified "yes," but it is not a common or guaranteed outcome.

While drug-induced liver injury (DILI) is an uncommon adverse event in the general population, some antivirals, particularly older antiretrovirals, are known to more frequently cause elevations in liver enzymes. In some instances, severe hepatotoxicity can occur, emphasizing the importance of monitoring and understanding the risks associated with these medications.